Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 318

1.

From a single meeting to a scientific community: Quantification of the "Advances in Neuroblastoma Research Association" network.

Berthold F.

Pediatr Blood Cancer. 2019 Jun;66(6):e27696. doi: 10.1002/pbc.27696. Epub 2019 Mar 8. No abstract available.

PMID:
30848089
2.

High-Density Molded Cellulose Fibers and Transparent Biocomposites Based on Oriented Holocellulose.

Yang X, Berthold F, Berglund LA.

ACS Appl Mater Interfaces. 2019 Mar 13;11(10):10310-10319. doi: 10.1021/acsami.8b22134. Epub 2019 Feb 27.

PMID:
30762342
3.

Are network growth and the contributions to congresses associated with publication success? A pediatric oncology model.

Berthold F, Bartenhagen C, Krempel L.

PLoS One. 2019 Jan 25;14(1):e0210994. doi: 10.1371/journal.pone.0210994. eCollection 2019. Erratum in: PLoS One. 2019 Feb 13;14(2):e0212536.

4.

A mechanistic classification of clinical phenotypes in neuroblastoma.

Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altmüller J, Nürnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, Büttner R, Eggert A, Speleman F, O'Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A, Westermann F, Schulte JH, Peifer M, Fischer M.

Science. 2018 Dec 7;362(6419):1165-1170. doi: 10.1126/science.aat6768.

PMID:
30523111
5.

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, Helsmoortel HH, Vermeulen J, Noguera R, Berbegall AP, Combaret V, Schleiermacher G, Laureys G, Schramm A, Schulte JH, Rahmann S, Bienertová-Vašků J, Mazánek P, Jeison M, Ash S, Hogarty MD, Moreno-Smith M, Barbieri E, Shohet J, Berthold F, Van Maerken T, Speleman F, Fischer M, De Preter K, Mestdagh P, Vandesompele J.

JCI Insight. 2018 Dec 6;3(23). pii: 97021. doi: 10.1172/jci.insight.97021.

6.

THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.

Greiner J, Schrappe M, Claviez A, Zimmermann M, Niemeyer C, Kolb R, Eberl W, Berthold F, Bergsträsser E, Gnekow A, Lassay E, Vorwerk P, Lauten M, Sauerbrey A, Rischewski J, Beilken A, Henze G, Korte W, Möricke A; THROMBOTECT Study Investigators.

Haematologica. 2019 Apr;104(4):756-765. doi: 10.3324/haematol.2018.194175. Epub 2018 Sep 27.

7.

Genetic structure and sex-biased gene flow in the history of southern African populations.

Bajić V, Barbieri C, Hübner A, Güldemann T, Naumann C, Gerlach L, Berthold F, Nakagawa H, Mpoloka SW, Roewer L, Purps J, Stoneking M, Pakendorf B.

Am J Phys Anthropol. 2018 Nov;167(3):656-671. doi: 10.1002/ajpa.23694. Epub 2018 Sep 7.

PMID:
30192370
8.

Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T.

Br J Cancer. 2018 Aug;119(3):282-290. doi: 10.1038/s41416-018-0169-8. Epub 2018 Jul 11.

PMID:
29991700
9.

Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.

Suttorp M, Schulze P, Glauche I, Göhring G, von Neuhoff N, Metzler M, Sedlacek P, de Bont ESJM, Balduzzi A, Lausen B, Aleinikova O, Sufliarska S, Henze G, Strauss G, Eggert A, Kremens B, Groll AH, Berthold F, Klein C, Groß-Wieltsch U, Sykora KW, Borkhardt A, Kulozik AE, Schrappe M, Nowasz C, Krumbholz M, Tauer JT, Claviez A, Harbott J, Kreipe HH, Schlegelberger B, Thiede C.

Leukemia. 2018 Jul;32(7):1657-1669. doi: 10.1038/s41375-018-0179-9. Epub 2018 Jun 20.

PMID:
29925908
10.

Preserving Cellulose Structure: Delignified Wood Fibers for Paper Structures of High Strength and Transparency.

Yang X, Berthold F, Berglund LA.

Biomacromolecules. 2018 Jul 9;19(7):3020-3029. doi: 10.1021/acs.biomac.8b00585. Epub 2018 May 23.

PMID:
29757614
11.

Computer-Based Exercise Program: Effects of a 12-Week Intervention on Mood and Fatigue in Pediatric Patients With Cancer
.

Platschek AM, Kehe L, Abeln V, Berthold F, Simon T, Strüder H.

Clin J Oncol Nurs. 2017 Dec 1;21(6):E280-E286. doi: 10.1188/17.CJON.E280-E286.

PMID:
29149133
12.

Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J.

Pediatr Hematol Oncol. 2017 Aug;34(5):308-319. doi: 10.1080/08880018.2017.1373314. Epub 2017 Nov 17.

PMID:
29148865
13.

Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.

Rosswog C, Schmidt R, Oberthuer A, Juraeva D, Brors B, Engesser A, Kahlert Y, Volland R, Bartenhagen C, Simon T, Berthold F, Hero B, Faldum A, Fischer M.

Neoplasia. 2017 Dec;19(12):982-990. doi: 10.1016/j.neo.2017.09.006. Epub 2017 Nov 5.

14.

Retrospective analysis of relapsed abdominal high-risk neuroblastoma.

Dübbers M, Simon T, Berthold F, Fischer J, Volland R, Hero B, Cernaianu G.

J Pediatr Surg. 2018 Mar;53(3):558-566. doi: 10.1016/j.jpedsurg.2017.09.002. Epub 2017 Sep 11.

PMID:
29021103
15.

Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

Peinemann F, van Dalen EC, Enk H, Berthold F.

Cochrane Database Syst Rev. 2017 Aug 25;8:CD010685. doi: 10.1002/14651858.CD010685.pub3. Review.

16.

Nanobody-mediated resistance to Grapevine fanleaf virus in plants.

Hemmer C, Djennane S, Ackerer L, Hleibieh K, Marmonier A, Gersch S, Garcia S, Vigne E, Komar V, Perrin M, Gertz C, Belval L, Berthold F, Monsion B, Schmitt-Keichinger C, Lemaire O, Lorber B, Gutiérrez C, Muyldermans S, Demangeat G, Ritzenthaler C.

Plant Biotechnol J. 2018 Feb;16(2):660-671. doi: 10.1111/pbi.12819. Epub 2017 Oct 6.

17.

Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015.

Berthold F, Spix C, Kaatsch P, Lampert F.

Paediatr Drugs. 2017 Dec;19(6):577-593. doi: 10.1007/s40272-017-0251-3.

18.

Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.

Fischer J, Pohl A, Volland R, Hero B, Dübbers M, Cernaianu G, Berthold F, von Schweinitz D, Simon T.

BMC Cancer. 2017 Aug 4;17(1):520. doi: 10.1186/s12885-017-3493-0.

19.

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.

Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD.

Expert Opin Drug Discov. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Review.

PMID:
28604107
20.

2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors.

Simon T, Hero B, Schulte JH, Deubzer H, Hundsdoerfer P, von Schweinitz D, Fuchs J, Schmidt M, Prasad V, Krug B, Timmermann B, Leuschner I, Fischer M, Langer T, Astrahantseff K, Berthold F, Lode H, Eggert A.

Klin Padiatr. 2017 May;229(3):147-167. doi: 10.1055/s-0043-103086. Epub 2017 May 30.

PMID:
28561228
21.

Feasibility, Risk Profile and Diagnostic Yield of Stereotactic Biopsy in Children and Young Adults with Brain Lesions.

Hamisch C, Blau T, Klinger K, Kickingereder P, Ruess D, Galldiks N, Berthold F, Simon T, Grau S, Ruge MI.

Klin Padiatr. 2017 May;229(3):133-141. doi: 10.1055/s-0043-101908. Epub 2017 May 30. Review.

PMID:
28561225
22.

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D.

J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. Review.

23.

The 50 distal amino acids of the 2AHP homing protein of Grapevine fanleaf virus elicit a hypersensitive reaction on Nicotiana occidentalis.

Martin IR, Vigne E, Berthold F, Komar V, Lemaire O, Fuchs M, Schmitt-Keichinger C.

Mol Plant Pathol. 2018 Mar;19(3):731-743. doi: 10.1111/mpp.12558. Epub 2017 May 15.

PMID:
28387986
24.

Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

Kraal KC, Bleeker GM, van Eck-Smit BL, van Eijkelenburg NK, Berthold F, van Noesel MM, Caron HN, Tytgat GA.

Eur J Cancer. 2017 May;76:188-196. doi: 10.1016/j.ejca.2016.12.013. Epub 2017 Mar 19.

PMID:
28329731
25.

Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group.

Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GA, Brock PR, Haber M, Park JR, Berthold F.

Cancer. 2017 Apr 1;123(7):1095-1105. doi: 10.1002/cncr.30380. Epub 2016 Dec 16. Review.

26.

Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.

Schumacher-Kuckelkorn R, Volland R, Gradehandt A, Hero B, Simon T, Berthold F.

Pediatr Blood Cancer. 2017 Jan;64(1):46-56. doi: 10.1002/pbc.26184. Epub 2016 Sep 22.

PMID:
27654028
27.

γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets.

Dorneburg C, Goß AV, Fischer M, Roels F, Barth TF, Berthold F, Kappler R, Oswald F, Siveke JT, Molenaar JJ, Debatin KM, Beltinger C.

Oncotarget. 2016 Sep 27;7(39):62799-62813. doi: 10.18632/oncotarget.11715.

28.

Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed.

Decarolis B, Simon T, Krug B, Leuschner I, Vokuhl C, Kaatsch P, von Schweinitz D, Klingebiel T, Mueller I, Schweigerer L, Berthold F, Hero B.

BMC Cancer. 2016 Jul 27;16:542. doi: 10.1186/s12885-016-2513-9.

29.

Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma.

Powers JT, Tsanov KM, Pearson DS, Roels F, Spina CS, Ebright R, Seligson M, de Soysa Y, Cahan P, Theißen J, Tu HC, Han A, Kurek KC, LaPier GS, Osborne JK, Ross SJ, Cesana M, Collins JJ, Berthold F, Daley GQ.

Nature. 2016 Jul 14;535(7611):246-51. doi: 10.1038/nature18632. Epub 2016 Jul 6.

30.

Display of whole proteins on inner and outer surfaces of grapevine fanleaf virus-like particles.

Belval L, Hemmer C, Sauter C, Reinbold C, Fauny JD, Berthold F, Ackerer L, Schmitt-Keichinger C, Lemaire O, Demangeat G, Ritzenthaler C.

Plant Biotechnol J. 2016 Dec;14(12):2288-2299. doi: 10.1111/pbi.12582. Epub 2016 Jul 29.

31.

Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review.

Peinemann F, van Dalen EC, Berthold F.

Klin Padiatr. 2016 Apr;228(3):130-4. doi: 10.1055/s-0042-103158. Epub 2016 Apr 4. Review.

PMID:
27043079
32.

Retinoic Acid for High-risk Neuroblastoma Patients after Autologous Stem Cell Transplantation - Cochrane Review.

Peinemann F, van Dalen EC, Berthold F.

Klin Padiatr. 2016 Apr;228(3):124-9. doi: 10.1055/s-0042-101169. Epub 2016 Mar 24. Review.

PMID:
27011226
33.

Jack-of-all-trades effects drive biodiversity-ecosystem multifunctionality relationships in European forests.

van der Plas F, Manning P, Allan E, Scherer-Lorenzen M, Verheyen K, Wirth C, Zavala MA, Hector A, Ampoorter E, Baeten L, Barbaro L, Bauhus J, Benavides R, Benneter A, Berthold F, Bonal D, Bouriaud O, Bruelheide H, Bussotti F, Carnol M, Castagneyrol B, Charbonnier Y, Coomes D, Coppi A, Bastias CC, Muhie Dawud S, De Wandeler H, Domisch T, Finér L, Gessler A, Granier A, Grossiord C, Guyot V, Hättenschwiler S, Jactel H, Jaroszewicz B, Joly FX, Jucker T, Koricheva J, Milligan H, Müller S, Muys B, Nguyen D, Pollastrini M, Raulund-Rasmussen K, Selvi F, Stenlid J, Valladares F, Vesterdal L, Zielínski D, Fischer M.

Nat Commun. 2016 Mar 24;7:11109. doi: 10.1038/ncomms11109.

34.

Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.

van Wezel EM, Decarolis B, Stutterheim J, Zappeij-Kannegieter L, Berthold F, Schumacher-Kuckelkorn R, Simon T, Fiocco M, van Noesel MM, Caron HN, van der Schoot CE, Hero B, Tytgat GAM.

Eur J Cancer. 2016 Feb;54:149-158. doi: 10.1016/j.ejca.2015.11.007. Epub 2016 Jan 12.

PMID:
26796600
35.

Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.

Ikram F, Ackermann S, Kahlert Y, Volland R, Roels F, Engesser A, Hertwig F, Kocak H, Hero B, Dreidax D, Henrich KO, Berthold F, Nürnberg P, Westermann F, Fischer M.

Mol Oncol. 2016 Feb;10(2):344-59. doi: 10.1016/j.molonc.2015.10.020. Epub 2015 Nov 7.

36.

Stereotactic intracavitary brachytherapy with P-32 for cystic craniopharyngiomas in children.

Maarouf M, El Majdoub F, Fuetsch M, Hoevels M, Lehrke R, Berthold F, Voges J, Sturm V.

Strahlenther Onkol. 2016 Mar;192(3):157-65. doi: 10.1007/s00066-015-0910-7. Epub 2015 Nov 5.

PMID:
26541336
37.

Telomerase activation by genomic rearrangements in high-risk neuroblastoma.

Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann JM, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Mariappan A, Heynck S, Mariotti E, Henrich KO, Gloeckner C, Bosco G, Leuschner I, Schweiger MR, Savelyeva L, Watkins SC, Shao C, Bell E, Höfer T, Achter V, Lang U, Theissen J, Volland R, Saadati M, Eggert A, de Wilde B, Berthold F, Peng Z, Zhao C, Shi L, Ortmann M, Büttner R, Perner S, Hero B, Schramm A, Schulte JH, Herrmann C, O'Sullivan RJ, Westermann F, Thomas RK, Fischer M.

Nature. 2015 Oct 29;526(7575):700-4. doi: 10.1038/nature14980. Epub 2015 Oct 14.

38.

Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL.

J Clin Oncol. 2015 Sep 20;33(27):3008-17. doi: 10.1200/JCO.2014.59.4648. Epub 2015 Aug 24. Review.

39.

Incidence, Trends, and Survival of Children With Embryonal Tumors.

Tulla M, Berthold F, Graf N, Rutkowski S, von Schweinitz D, Spix C, Kaatsch P.

Pediatrics. 2015 Sep;136(3):e623-32. doi: 10.1542/peds.2015-0224.

40.

Correction factors for self-selection when evaluating screening programmes.

Spix C, Berthold F, Hero B, Michaelis J, Schilling FH.

J Med Screen. 2016 Mar;23(1):44-9. doi: 10.1177/0969141315597959. Epub 2015 Jul 29.

PMID:
26223516
41.

Holocellulose Nanofibers of High Molar Mass and Small Diameter for High-Strength Nanopaper.

Galland S, Berthold F, Prakobna K, Berglund LA.

Biomacromolecules. 2015 Aug 10;16(8):2427-35. doi: 10.1021/acs.biomac.5b00678. Epub 2015 Jul 20.

PMID:
26151837
42.

Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.

Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M.

Genome Biol. 2015 Jun 25;16:133. doi: 10.1186/s13059-015-0694-1.

43.

Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.

Peinemann F, Tushabe DA, van Dalen EC, Berthold F.

Cochrane Database Syst Rev. 2015 May 19;(5):CD010774. doi: 10.1002/14651858.CD010774.pub2. Review.

PMID:
25989478
44.

Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma.

van Wezel EM, Stutterheim J, Vree F, Zappeij-Kannegieter L, Decarolis B, Hero B, Berthold F, Schumacher-Kuckelkorn R, Simon T, Fiocco M, Voermans C, van Noesel MM, Caron HN, van der Schoot CE, Tytgat GA; GPOH MRD Study Group.

Pediatr Blood Cancer. 2015 Aug;62(8):1368-73. doi: 10.1002/pbc.25507. Epub 2015 May 4.

PMID:
25939774
45.

Pancreatic Steatosis Demonstrated at MR Imaging in the General Population: Clinical Relevance.

Kühn JP, Berthold F, Mayerle J, Völzke H, Reeder SB, Rathmann W, Lerch MM, Hosten N, Hegenscheid K, Meffert PJ.

Radiology. 2015 Jul;276(1):129-36. doi: 10.1148/radiol.15140446. Epub 2015 Feb 5.

46.

Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation.

Peinemann F, van Dalen EC, Tushabe DA, Berthold F.

Cochrane Database Syst Rev. 2015 Jan 29;1:CD010685. doi: 10.1002/14651858.CD010685.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Aug 25;8:CD010685.

PMID:
25634649
47.

Sample size calculation for the one-sample log-rank test.

Schmidt R, Kwiecien R, Faldum A, Berthold F, Hero B, Ligges S.

Stat Med. 2015 Mar 15;34(6):1031-40. doi: 10.1002/sim.6394. Epub 2014 Dec 11.

PMID:
25500942
48.

FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.

Ackermann S, Kocak H, Hero B, Ehemann V, Kahlert Y, Oberthuer A, Roels F, Theißen J, Odenthal M, Berthold F, Fischer M.

BMC Cancer. 2014 Nov 18;14:840. doi: 10.1186/1471-2407-14-840.

49.

Suppression of xylan endotransglycosylase PtxtXyn10A affects cellulose microfibril angle in secondary wall in aspen wood.

Derba-Maceluch M, Awano T, Takahashi J, Lucenius J, Ratke C, Kontro I, Busse-Wicher M, Kosik O, Tanaka R, Winzéll A, Kallas Å, Leśniewska J, Berthold F, Immerzeel P, Teeri TT, Ezcurra I, Dupree P, Serimaa R, Mellerowicz EJ.

New Phytol. 2015 Jan;205(2):666-81. doi: 10.1111/nph.13099. Epub 2014 Oct 13.

50.

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M.

Clin Cancer Res. 2015 Apr 15;21(8):1904-15. doi: 10.1158/1078-0432.CCR-14-0817. Epub 2014 Sep 17.

Supplemental Content

Loading ...
Support Center